NYSE:AZN Astrazeneca Q3 2026 Earnings Date & Estimates $172.03 +0.54 (+0.32%) Closing price 10/26/2026 03:59 PM EasternExtended Trading$171.91 -0.12 (-0.07%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Astrazeneca is estimated to report Q3 2026 earnings on Friday, October 30, 2026, before market opens. The conference call is scheduled for 10:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 30, 2026TimeBefore Market OpensConference Call10:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Astrazeneca in Q3 2026Astrazeneca is expected to post earnings of $2.60 per share on revenue of $16.01 billion. In the same quarter a year earlier Astrazeneca reported $2.38 per share on revenue of $15.19 billion. Astrazeneca last reported on July 27, 2026, posting $2.63 per share and beating the $2.50 consensus estimate. Astrazeneca has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS$2.60Expected Revenue$16.01 billionPrior-Year EPS$2.38Prior-Year Revenue$15.19 billionExpected EPS Growth+9.2%Expected Revenue Growth+5.4%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$2.63 (Beat by +$0.13)Last Quarter Revenue$15.38 billionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Astrazeneca Q3 2026 Earnings FAQ When does Astrazeneca report Q3 2026 earnings? Astrazeneca (NYSE:AZN) is estimated to report Q3 2026 earnings on Friday, October 30, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Astrazeneca's Q3 2026 earnings call? Astrazeneca's Q3 2026 earnings conference call is scheduled for Friday, October 30, 2026 at 10:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Astrazeneca? Analysts expect Astrazeneca to post earnings of $2.60 per share for Q3 2026. How much revenue is Astrazeneca expected to report? The consensus revenue estimate for Astrazeneca is $16.01 billion for Q3 2026. Astrazeneca Earnings HeadlinesAstraZeneca's stomach cancer drug extends overall survival, late-stage trial data findsOctober 26 at 8:09 AM | reuters.comAstrazeneca Reports Higher Patient Survival Rates in Stomach, Lung-Cancer Drug TrialsOctober 26 at 8:09 AM | finance.yahoo.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end. | Banyan Hill Publishing (Ad)Is AstraZeneca's Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?October 26 at 7:45 AM | 247wallst.comAstraZeneca Readies New Portfolio of Targeted Cancer TherapiesOctober 25 at 8:12 PM | wsj.comAstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage studyOctober 25 at 1:18 PM | msn.comSee More Astrazeneca Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astrazeneca? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astrazeneca and other key companies, straight to your email. Email Address About AstrazenecaAstrazeneca (NYSE:AZN) is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders. Among its well-known products are Tagrisso and Imfinzi in oncology; Farxiga for cardiovascular, kidney and metabolic conditions; Symbicort and Fasenra for respiratory diseases; and Soliris and Ultomiris for certain rare diseases. The company also develops vaccines and other biologic therapies through selected collaborations and research programs. AstraZeneca was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group. Its shares trade on the London Stock Exchange, and its American Depositary Receipts trade on the New York Stock Exchange under the symbol AZN. Pascal Soriot has served as the company’s chief executive officer since 2012.View Astrazeneca ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings T-Mobile US (10/28/2026)Alphabet (10/28/2026)Alphabet (10/28/2026)Carvana (10/28/2026)eBay (10/28/2026)Garmin (10/28/2026)O'Reilly Automotive (10/28/2026)Equinor ASA (10/28/2026)Phillips 66 (10/28/2026)AON (10/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
